RWJ-51204

drugbox
IUPAC_name = 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo [4,5] imidazo [1,2a] pyridine-4-N-(2-fluorophenyl)carboxamide

---

CAS_number = 205701-85-5
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C=21|H=19|F=2|N=3|O=3
molecular_weight = 399.390 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

RWJ-51204 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

RWJ-51204 is a nonselective partial agonist at GABA_A receptors. [Atack JR. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. "Current Drug Targets. CNS and Neurological Disorders". 2003 Aug;2(4):213-32.] It produces primarily anxiolytic effects at low doses, with sedative, ataxia and muscle relaxant effects only appearing at some 20x the effective anxiolytic dose. [Dubinsky B, Vaidya AH, Rosenthal DI, Hochman C, Crooke JJ, DeLuca S, DeVine A, Cheo-Isaacs CT, Carter AR, Jordan AD, Reitz AB, Shank RP. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo [4,5] imidazo [1,2a] pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. "Journal of Pharmacology and Experimental Therapeutics". 2002 Nov;303(2):777-90.] It was discovered by researchers at the pharmaceutical company Johnson & Johnson, [Reitz AB, Jordan AD, Sanfilippo PJ, and Vavouyios-Smith A (1998) [http://www.google.com/patents?id=J0ACAAAAEBAJ&dq=5817668 U.S. Patent 5,817,668] .] [Cohen JH, Maryanoff CA, Stefanik SM, Sorgi KL, Villani FJ. Process research for the synthesis of RWJ-51204, a novel anxiolytic agent. "Organic Process Research & Development". 1999; 3(4):260-265.] but its development has been discontinued.

References